Parallel Advisors’s Abeona Therapeutics ABEO Stock Holding History

Parallel Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.47K	Hold	400	–	–	﹤0.01%	3470
2026 Q1	$1.79K	Hold	400	–	–	﹤0.01%	3406
2025 Q4	$2.11K	Hold	400	–	–	﹤0.01%	3121
2025 Q3	$2.11K	Hold	400	–	–	﹤0.01%	3034
2025 Q2	$2.27K	Hold	400	–	–	﹤0.01%	3007
2025 Q1	$1.9K	Hold	400	–	–	﹤0.01%	2992
2024 Q4	$2.23K	Hold	400	–	–	﹤0.01%	2934
2024 Q3	$2.53K	Hold	400	–	–	﹤0.01%	2826
2024 Q2	$1.7K	Hold	400	–	–	﹤0.01%	2846
2024 Q1	$2.9K	Hold	400	–	–	﹤0.01%	2702
2023 Q4	$2K	Hold	400	–	–	﹤0.01%	2807
2023 Q3	$1.68K	Hold	400	–	–	﹤0.01%	2871
2023 Q2	$1.61K	Hold	400	–	–	﹤0.01%	2814
2023 Q1	$1.13K	Hold	400	–	–	﹤0.01%	2924
2022 Q4	$1.23K	Hold	400	–	–	﹤0.01%	2850
2022 Q3	$1K	Hold	400	–	–	﹤0.01%	2823
2022 Q2	$2K	Hold	400	–	–	﹤0.01%	2520
2022 Q1	$3K	Buy	+400	New	+$2.75K	﹤0.01%	2432

Other funds holding ABEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

OIA

OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Parallel Advisors's ABEO Position: Q2 2026 in Review

Parallel Advisors held its Abeona Therapeutics (ABEO) position steady in Q2 2026 at 400 shares worth $2.47K. The position accounts for ﹤0.01% of the portfolio, ranked #3470.

Parallel Advisors first reported a position in ABEO in Q1 2022 and has held it in 18 quarters since. The position peaked at $3K in Q1 2022. 40 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

Parallel Advisors held 400 shares of Abeona Therapeutics worth $2.47K as of Q2 2026.
Parallel Advisors left its Abeona Therapeutics share count unchanged in Q2 2026.
Abeona Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3470 holding.
Parallel Advisors first reported a position in Abeona Therapeutics in Q1 2022 and has held it in 18 quarters since.
Parallel Advisors's Abeona Therapeutics position peaked at $3K in Q1 2022.
40 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.